

Camilla Pilati

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3248449/publications.pdf>

Version: 2024-02-01

32
papers

3,817
citations

331538

21
h-index

395590

33
g-index

33
all docs

33
docs citations

33
times ranked

6848
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic value of the PrP ^C -ILK-IDO1 axis in the mesenchymal colorectal cancer subtype. <i>Oncolmmunology</i> , 2021, 10, 1940674.	2.1	11
2	Deciphering the Role of Intestinal Crypt Cell Populations in Resistance to Chemotherapy. <i>Cancer Research</i> , 2021, 81, 2730-2744.	0.4	4
3	Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4768-4780.	3.2	25
4	CD200 expression is a feature of solid pseudopapillary neoplasms of the pancreas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 105-109.	1.4	19
5	The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer. <i>EBioMedicine</i> , 2019, 46, 94-104.	2.7	24
6	Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis. <i>BMC Cancer</i> , 2019, 19, 232.	1.1	37
7	Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma. <i>Pancreas</i> , 2019, 48, 70-76.	0.5	11
8	Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 939-947.	1.4	36
9	Unresectable metastatic colorectal cancer patient cured with cetuximab-based chemotherapy: a case report with new molecular insights. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, E23-E27.	0.6	7
10	PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications. <i>Human Pathology</i> , 2018, 81, 157-165.	1.1	44
11	Histo-molecular oncogenesis of pancreatic cancer: From precancerous lesions to invasive ductal adenocarcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2018, 10, 317-327.	0.8	22
12	Mutational signature analysis identifies <i>MUTYH</i> deficiency in colorectal cancers and adrenocortical carcinomas. <i>Journal of Pathology</i> , 2017, 242, 10-15.	2.1	130
13	CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification. <i>Annals of Oncology</i> , 2017, 28, 1032-1035.	0.6	43
14	Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. <i>Gastroenterology</i> , 2017, 152, 880-894.e6.	0.6	290
15	A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1200-1212.	3.2	21
16	Genotype-phenotype correlation of CTNNB1 mutations reveals different β -catenin activity associated with liver tumor progression. <i>Hepatology</i> , 2016, 64, 2047-2061.	3.6	222
17	Wild-type AAV Insertions in Hepatocellular Carcinoma Do Not Inform Debate Over Genotoxicity Risk of Vectorized AAV. <i>Molecular Therapy</i> , 2016, 24, 660-661.	3.7	33
18	Sulfheme formation during homocysteine S-oxygenation by catalase in cancers and neurodegenerative diseases. <i>Nature Communications</i> , 2016, 7, 13386.	5.8	30

#	ARTICLE	IF	CITATIONS
19	Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 4057-4066.	3.2	433
20	AAV2 and Hepatocellular Carcinoma. <i>Human Gene Therapy</i> , 2016, 27, 211-213.	1.4	8
21	Mutations leading to constitutive active gp130/JAK1/STAT3 pathway. <i>Cytokine and Growth Factor Reviews</i> , 2015, 26, 499-506.	3.2	42
22	Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers. <i>British Journal of Cancer</i> , 2015, 113, 680-685.	2.9	11
23	Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. <i>Nature Genetics</i> , 2015, 47, 1187-1193.	9.4	387
24	Genomic Profiling of Hepatocellular Adenomas Reveals Recurrent FRK-Activating Mutations and the Mechanisms of Malignant Transformation. <i>Cancer Cell</i> , 2014, 25, 428-441.	7.7	240
25	Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer. <i>Pharmacogenomics</i> , 2014, 15, 1043-1052.	0.6	16
26	A <i>let-7</i> microRNA-Binding Site Polymorphism in <i>KRAS</i> Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy. <i>Clinical Cancer Research</i> , 2014, 20, 4499-4510.	3.2	55
27	High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. <i>Nature Communications</i> , 2013, 4, 2218.	5.8	513
28	Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma. <i>Oncolmmunology</i> , 2013, 2, e27090.	2.1	39
29	STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. <i>Haematologica</i> , 2013, 98, 1748-1752.	1.7	50
30	GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. <i>Journal of Hepatology</i> , 2012, 56, 184-191.	1.8	354
31	Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. <i>Journal of Experimental Medicine</i> , 2011, 208, 1359-1366.	4.2	218
32	Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. <i>Nature</i> , 2009, 457, 200-204.	13.7	437